Distinguishing Invasive from Chronic Pulmonary Infections: Host Pentraxin 3 and Fungal Siderophores in Bronchoalveolar Lavage Fluids
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic
Typ dokumentu časopisecké články
Grantová podpora
21-17044S
Grant Agency of Czech Republic
SGS01-2021
Internal Grant Agency of University of Ostrava
CZ.02.1.01/0.0/0.0/16_025/000739
Ministry of Education, Youth and Sport of the Czech Republic
PubMed
36422015
PubMed Central
PMC9694386
DOI
10.3390/jof8111194
PII: jof8111194
Knihovny.cz E-zdroje
- Klíčová slova
- bronchoalveolar lavage fluid, invasive fungal disease, non-neutropenic, pentraxin-3, pulmonary aspergillosis, triacetylfusarinine C,
- Publikační typ
- časopisecké články MeSH
The multiple forms of pulmonary aspergillosis caused by Aspergillus species are the most common respiratory mycoses. Although invasive, the analysis of diagnostic biomarkers in bronchoalveolar lavage fluid (BALF) is a clinical standard for diagnosing these conditions. The BALF samples from 22 patients with proven or probable aspergillosis were assayed for human pentraxin 3 (Ptx3), fungal ferricrocin (Fc), and triacetylfusarinine C (TafC) in a retrospective study. The infected group included patients with invasive pulmonary aspergillosis (IPA) and chronic aspergillosis (CPA). The BALF data were compared to a control cohort of 67 patients with invasive pulmonary mucormycosis (IPM), non-Aspergillus colonization, or bacterial infections. The median Ptx3 concentrations in patients with and without aspergillosis were 4545.5 and 242.0 pg/mL, respectively (95% CI, p < 0.05). The optimum Ptx3 cutoff for IPA was 2545 pg/mL, giving a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 100, 98, 95, and 100%, respectively. The median Ptx3 concentration for IPM was high at 4326 pg/mL. Pentraxin 3 assay alone can distinguish IPA from CPA and invasive fungal disease from colonization. Combining Ptx3 and TafC assays enabled the diagnostic discrimination of IPM and IPA, giving a specificity and PPV of 100%.
California Institute for Medical Research 2260 Clove Dr San Jose CA 95128 USA
Department of Clinical Biochemistry AGEL Hornická poliklinika s r o 70200 Ostrava Czech Republic
Department of Hemato oncology University Hospital of Ostrava 70800 Ostrava Czech Republic
Department of Immunology Public Health Institute in Ostrava 70200 Ostrava Czech Republic
Department of Lung Disease and Tuberculosis University Hospital Ostrava 70800 Ostrava Czech Republic
Department of Pneumology and Phthisiology Ostrava City Hospital 72880 Ostrava Czech Republic
Institute of Microbiology of the Czech Academy of Sciences 14220 Prague Czech Republic
Lung Department Krnov Combined Medical Facility 79401 Krnov Czech Republic
Zobrazit více v PubMed
Bassetti M., Azoulay E., Kullberg B.J., Ruhnke M., Shoham S., Vazquez J., Giacobbe D.R., Calandra T. EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021;72:S121–S127. doi: 10.1093/cid/ciaa1751. PubMed DOI
Latge J.P., Chamilos G. Aspergillus fumigatus and Aspergillosis in 2019. Clin. Microbiol. Rev. 2019;33:e00140-18. doi: 10.1128/CMR.00140-18. PubMed DOI PMC
Dobias R., Jaworska P., Tomaskova H., Kanova M., Lyskova P., Vrba Z., Holub C., Svobodová L., Hamal P., Raska M. Diagnostic value of serum galactomannan, (1,3)-β-d-glucan, and Aspergillus fumigatus-specific IgA and IgG assays for invasive pulmonary aspergillosis in non-neutropenic patients. Mycoses. 2018;61:576–586. doi: 10.1111/myc.12765. PubMed DOI
Koehler P., Bassetti M., Chakrabarti A., Chen S.C.A., Colombo A.L., Hoenigl M., Klimko N., Lass-Flörl C., Oladele R.O., Vinh D.C., et al. Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet. Infect. Dis. 2020;21:e149–e162. doi: 10.1016/S1473-3099(20)30847-1. PubMed DOI PMC
Meersseman W., Lagrou K., Maertens J., Wilmer A., Hermans G., Vanderschueren S., Spriet I., Verbeken E., Van Wijngaerden E. Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients. Am. J. Resp. Crit. Care Med. 2008;177:27–34. doi: 10.1164/rccm.200704-606OC. PubMed DOI
Cao X.J., Li Y.P., Xie L.M., Zhang H.L., Qin Y.S., Guo X.G. Diagnostic Accuracy of Bronchoalveolar Lavage Fluid Galactomannan for Invasive Aspergillosis. Biomed Res. Int. 2020;2020:5434589. doi: 10.1155/2020/5434589. PubMed DOI PMC
Škríba A., Pluháček T., Palyzová A., Nový Z., Lemr K., Hajdúch M., Petřík M., Havlíček V. Early and Non-invasive Diagnosis of Aspergillosis Revealed by Infection Kinetics Monitored in a Rat Model. Front. Microbiol. 2018;9:2356. doi: 10.3389/fmicb.2018.02356. PubMed DOI PMC
Luptáková D., Pluháček T., Petřík M., Novák J., Palyzová A., Sokolová L., Škríba A., Šedivá B., Lemr K., Havlíček V. Non-invasive and invasive diagnoses of aspergillosis in a rat model by mass spectrometry. Sci. Rep. 2017;7:16523. doi: 10.1038/s41598-017-16648-z. PubMed DOI PMC
Kabbani D., Bhaskaran A., Singer L.G., Bhimji A., Rotstein C., Keshavjee S., Liles W.C., Husain S. Pentraxin 3 levels in bronchoalveolar lavage fluid of lung transplant recipients with invasive aspergillosis. J. Heart Lung Transplant. 2017;36:973–979. doi: 10.1016/j.healun.2017.04.007. PubMed DOI
Li H., Liu L., Zhou W., Rui Y., He B., Shi Y., Su X. Pentraxin 3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with pulmonary aspergillosis. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2019;25:504–510. doi: 10.1016/j.cmi.2018.06.015. PubMed DOI
Dobiáš R., Škríba A., Pluháček T., Petřík M., Palyzová A., Káňová M., Čubová E., Houšť J., Novák J., Stevens D.A., et al. Noninvasive Combined Diagnosis and Monitoring of Aspergillus and Pseudomonas Infections: Proof of Concept. J. Fungi. 2021;7:730. doi: 10.3390/jof7090730. PubMed DOI PMC
Ullmann A.J., Aguado J.M., Arikan-Akdagli S., Denning D.W., Groll A.H., Lagrou K., Lass-Florl C., Lewis R.E., Munoz P., Verweij P.E., et al. Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2018;24((Suppl. 1)):e1–e38. doi: 10.1016/j.cmi.2018.01.002. PubMed DOI
Rutuja H.P., Luptáková D., Havlíček V. Infection metallomics for critical care in the post-COVID era. Mass Spectrom. Rev. 2021 doi: 10.1002/mas.21755. PubMed DOI
Škríba A., Patil R.H., Hubáček P., Dobiáš R., Palyzová A., Marešová H., Pluháček T., Havlíček V. Rhizoferrin Glycosylation in Rhizopus microsporus. J. Fungi. 2020;6:89. doi: 10.3390/jof6020089. PubMed DOI PMC
Novák J., Škríba A., Havlíček V. CycloBranch 2: Molecular Formula Annotations Applied to imzML Data Sets in Bimodal Fusion and LC-MS Data Files. Anal. Chem. 2020;92:6844–6849. doi: 10.1021/acs.analchem.0c00170. PubMed DOI
R.C.T . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2020.
Thiele C., Hirschfeld G. Cutpointr: Improved estimation and validation of optimal cutpoints in R. arXiv. 2020 doi: 10.18637/jss.v098.i11.2002.09209 DOI
Narkhede S. Understanding auc-roc curve. Towards Data Sci. 2018;26:220–227.
Hoenigl M., Orasch T., Faserl K., Prattes J., Loeffler J., Springer J., Gsaller F., Reischies F., Duettmann W., Raggam R.B., et al. Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis. J. Infect. 2019;78:150–157. doi: 10.1016/j.jinf.2018.09.006. PubMed DOI PMC
Asai Y., Hiratsuka T., Ueda M., Kawamura Y., Asamizu S., Onaka H., Arioka M., Nishimura S., Yoshida M. Differential Biosynthesis and Roles of Two Ferrichrome-Type Siderophores, ASP2397/AS2488053 and Ferricrocin, in Acremonium persicinum. ACS Chem. Biol. 2022;17:207–216. doi: 10.1021/acschembio.1c00867. PubMed DOI
Pauwels N.S., Bracke K.R., Maes T., Van Pottelberge G.R., Garlanda C., Mantovani A., Joos G.F., Brusselle G.G. Cigarette smoke induces PTX3 expression in pulmonary veins of mice in an IL-1 dependent manner. Respir. Res. 2010;11:134. doi: 10.1186/1465-9921-11-134. PubMed DOI PMC
Kurt O.K., Tosun M., Kurt E.B., Talay F. Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation. 2015;38:89–93. doi: 10.1007/s10753-014-0010-3. PubMed DOI
Thulborn S.J., Dilpazir M., Haldar K., Mistry V., Brightling C.E., Barer M.R., Bafadhel M. Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD. Int. J. Chron. Obst. Pulm. Dis. 2017;12:1199–1205. doi: 10.2147/COPD.S123528. PubMed DOI PMC
Ishihara T., Haraguchi G., Kamiishi T., Tezuka D., Inagaki H., Isobe M. Sensitive assessment of activity of Takayasu’s arteritis by pentraxin3, a new biomarker. J. Am. Coll. Cardiol. 2011;57:1712–1713. doi: 10.1016/j.jacc.2010.10.058. PubMed DOI
Gamaletsou M.N., Denning D.W. Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection? Mycopathologia. 2017;182:1125–1129. doi: 10.1007/s11046-017-0176-y. PubMed DOI
Inforzato A., Bottazzi B., Garlanda C., Valentino S., Mantovani A. Pentraxins in humoral innate immunity. Adv. Exp. Med. Biol. 2012;946:1–20. doi: 10.1007/978-1-4614-0106-3_1. PubMed DOI
Current and Future Pathways in Aspergillus Diagnosis
Diagnosis of Aspergillosis in Horses
